trending Market Intelligence /marketintelligence/en/news-insights/trending/cukcamtafbclwoba8g4_sw2 content esgSubNav
In This List

Akcea Therapeutics names Ionis exec to its board

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Akcea Therapeutics names Ionis exec to its board

Akcea Therapeutics Inc. named Damien McDevitt to its board.

McDevitt is the chief business officer of Akcea's parent, Ionis Pharmaceuticals Inc. He will replace Stanley Crooke Ionis' founder, chairman and CEO — who has resigned from Akcea's board.

Before joining Ionis in June, McDevitt was senior vice president of corporate development at Acadia Pharmaceuticals Inc. He had also served in various global and strategic business roles at GlaxoSmithKline PLC.

Cambridge, Mass.-based Akcea Therapeutics is a biopharmaceutical company focused on developing and commercializing drugs to treat patients with serious and rare diseases.